Titanium and nitride oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population

Journal of Invasive Cardiology

Volumn 18, Issue 10, 2006, Pages 462-468

  Karjalainen, Pasi P ^a   Ylitalo, Antti ^a   Airaksinen, Juhani K E ^a  

^a SATAKUNTA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TITANIUM; TITANIUM DIOXIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; SAFETY; TREATMENT OUTCOME;

AGED; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; REGISTRIES; STENTS; TITANIUM; TREATMENT OUTCOME;

EID: 33749353486     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
3. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-1436.
4. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-1873.
5. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
6. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
7. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
8. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004;364:583-591.
9. Pache J, Dibra A, Mehilli J, et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005;26:1262-1268.
10. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
11. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (TSEARCH) registry. J Am Coll Cardiol 2005;45:1135-1141.
12. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: The TAXi trial. J Am Coll Cardiol 2005;45:308-311.
13. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849.
14. Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;20:3806-3813.
15. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve- month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
16. Garasic JM, Edelman ER, Squire JC, et al. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 2000;101:812-818.
17. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-2821.
18. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002;106:2859-2866.
19. Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000;356:1895-1897.
20. Vom Dahl J, Haager PK, Grube E, et al. Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. Am J Cardiol 2002;89:801-805.
21. Park SJ, Lee CW, Hong MK, et al. Comparison of gold-coated NIR stents with uncoated NIR stents in patients with coronary artery disease. Am J Cardiol 2002;89:872-875.
22. Steinemann SG. Titanium: The material of choice? Periodontol 2000. 1998;17:7-21.
23. Steinemann SG. Metal implants and surface reactions. Injury 1996;27(Suppl 3):SC16-SC22.
24. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride oxide for reduction of neointimal hyperplasia. Circulation 2001;104:928-933.
25. Windecker S, Simon R, Lins M, et al. Randomized comparison of a titanium-nitride oxide-coated stent with a stainless steel stent for coronary revascularization. The TINOX trial. Circulation 2005;111:2617-2622.
26. Buehl A, Zoefel P. SPSS 11: Introduction in Modern Data Analysis. 8th ed. Munich, Germany: Addison-Wesley, 2002.
27. Hofma SH, Ong AT, Aoki J, et al. One year clinical follow up of paclitaxel-eluting stents for acute myocardial infarction compared with sirolimus-eluting stents. Heart 2005;91:1176-1180.
28. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
29. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-953.
30. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
31. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-β1521.
32. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
33. Walpoth BH, Pavlicek M, Celik B, et al. Prevention of neointimal proliferation by immunosupression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001;19:487-492.
34. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
35. Dietz U, Holz N, Dauer C, et al. Shortening the stent length reduces restenosis with bare metal stents: Matched pair comparison of short stenting and conventional stenting. Heart 2006;92:80-84.
36. Hung-I Y, Shao-Kou L, Tin-Yi T, et al. Comparison of endothelial cells grown on different stent materials. J Biomed Mater Res A 2006;76:835-841.